Physician profile
Augustine Ahenkorah
NPI 1376118182
$1,699.07
in general payments reported to CMS, 2019-2025
22 companies · $1,217 in 2025
The $1,217 reported for 2025 was more than what 84% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $95.40 · 2024: $387 · 2025: $1,217.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,699.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,699.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $309.52 | 2023-2025 | Rexulti, Abilify Asimtufii |
| Lundbeck LLC | $169.29 | 2025 | Rexulti |
| Corium, LLC | $152.41 | 2023-2025 | Azstarys |
| Abbvie INC. | $151.68 | 2023-2025 | Vraylar |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $136.46 | 2024-2025 | Caplyta |
| Vanda Pharmaceuticals INC. | $134.03 | 2024-2025 | Fanapt, Hetlioz |
| Axsome Therapeutics, INC. | $124.10 | 2025 | Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $103.13 | 2024-2025 | Trintellix |
| Janssen Pharmaceuticals, INC | $50.62 | 2023-2025 | Spravato, Invega Trinza, Invega Sustenna |
| Supernus Pharmaceuticals, INC. | $47.16 | 2025 | Qelbree |
| Alkermes, INC. | $38.82 | 2025 | Aristada, Lybalvi |
| E.R. Squibb & Sons, L.L.C. | $35.81 | 2025 | Cobenfy |
| Bausch Health US, LLC | $33.38 | 2025 | Wellbutrin, Aplenzin |
| Neurocrine Biosciences, INC. | $32.12 | 2024 | Ingrezza |
| Tms Neurohealth Centers INC. | $25.99 | 2025 | Tms Neurohealth Centers INC. |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harmony Biosciences LLC | $25.80 | 2025 | |
| Idorsia Pharmaceuticals US INC | $24.49 | 2024 | Quviviq |
| Teva Pharmaceuticals USA, INC. | $24.14 | 2024 | Austedo Xr |
| Neuronetics, INC. | $23.54 | 2024 | Neurostar Tms Therapy System |
| Collegium Pharmaceutical, INC. | $21.72 | 2025 | Jornay Pm |
| Avadel Cns Pharmaceuticals, LLC | $20.99 | 2025 | Lumryz |
| Tris Pharma INC | $13.87 | 2025 | Dyanavel Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Augustine Ahenkorah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.